Posters

Long-term effects of OPE® technology combined with Light Modulation® (Eye-Light®) in the treatment of meibomian gland dysfunction (MGD)

Poster Details

First Author: A.Rodriguez SPAIN

Co Author(s):    M. Amesty   L. Primavera   J. Alio              

Abstract Details

Purpose:

To evaluate the long-term effects of the OPE® TECHNOLOGY combined with LIGHT MODULATION® (EYE-LIGHT®) protocol in the treatment of meibomian gland dysfunction (MGD) in a prospective study. OPE® TECHNOLOGY is a polychromatic light which uses thermal pulses and LIGHT MODULATION® is a unique technology of photobiomodulation that allows endogenous heating of the eyelids. The combine use of both stimulates the contraction of the meibomian glands and facilitates the spill of them, stabilizing the lipid layer of the tear.

Setting:

VISSUM MIRANZA, Alicante, Spain.

Methods:

Patients with refractory MGD to conventional treatments were selected and underwent 4 OPE®- LIGHT MODULATION® treatment sessions at baseline, 15, 30, 60 days. The follow up of the patients rich at 6 months after the last session. The ocular surface disease index (OSDI) score, subjective symptom score using VAS scale, height of the meniscus lacrimal, NIBUT (Non Invasive Break-Up Time), bulbar redness and meibography (Meibo-Scan) of the upper and lower eyelids, were assessed before each session of treatment and after 1, 3 and 6 months of the last session. The use of artificial tears was also recorded.

Results:

72 eyes of 36 patients (mean age ± SD, 58.7 ± 16.4 years) were enrolled. The OSDI score improved after the therapy from severe dry eye (41) to mild (22) at 60 days, and (21) after 6 months. The subjective symptoms with the VAS scale (range from 0-100) improved from 42 to 15 and 11 after the same time. The NIBUT values improved 3-4 seconds at 60 days and 3-6 seconds after 6 months. Frequency of administration of artificial tears decreased from 5.2 to 2.8 times a day. The height of the meniscus lacrimal, bulbar redness and meibography grading remained stable.

Conclusions:

Patients suffering MGD after receiving 4 consecutive sessions of EYE-LIGHT® using the OPE® TECHNOLOGY combined with the LIGHT MODULATION®, improved significantly the symptoms OSDI and VAS. NIBUT also improved and decreased the frequency of administration of artificial tears after 1 month of the last session. These values were maintained during the following 6 months showing the long-term effects of this treatment.

Financial Disclosure:

None